Physicians

Department / Division
Pathology / Pathology Clinical Services

Address
DUMC 3712
Durham, NC 27710

Office Telephone
919-684-6965

Fax Telephone
919-684-6962

Training

• MD, Duke University School of Medicine, 1999

Residency

• Pathology, Duke University Medical Center, 2004

Other Training

• PhD, Molecular Cancer Biology, Duke University Medical Center, 1999

Clinical Interests
Molecular diagnostic testing

Research Interests
Dr. Datto is a AP/CP/MGP board certified pathologist who specializes in molecular pathology. He is director of the Duke University Health System Clinical Molecular Diagnostics Laboratory. This CAP/CLIA certified laboratory does the majority of the DNA and RNA based high complexity molecular diagnostic testing for Duke patients and health care providers. Testing includes full gene sequencing and targeted mutation analysis for inherited diseases, targeted mutation and polymorphism analysis for somatic mutations in a variety of tumor types and disease conditions for prognostics and pharmacogenomic applications and quantitative analysis for viral load and minimal residual disease testing in patients with leukemias and lymphomas.

Dr. Datto also has an independent research program developing multigene assays to determine cancer patient specific prognoses in the context of breast and colon cancer with the ultimate goal of producing improved molecular diagnostic assays. The ultimate goal of this truly translational effort is the incorporation of genome wide expression profiling for prognosis and diagnosis into the clinical laboratories for routine patient care. This involves the study of factors that affect the precission and accuracy array-based predictors, as well as deriving novel diagnostic molecular targets. Finally, Dr. Datto has a strong research interest in resident and medical student education, specifically the development of web-base community tools for anatomic and clinical pathology education.

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Barry, WT; Kernagis, DN; Dressman, HK; Griffis, RJ; Hunter, JD; Olson, JA; Marks, JR; Ginsburg, GS; Marcom, PK; Nevins, JR; Geradts, J; Datto, MB. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. Journal of Clinical Oncology. 2010;28:2198-2206. (2010) Abstract

Crow, J; Youens, K; Michalowski, S; Perrine, G; Emhart, C; Johnson, F; Gerling, A; Kurtzberg, J; Goodman, BK; Sebastian, S; Rehder, CW; Datto, MB. Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis. The Journal of Molecular Diagnostics. 2010;12:530-537. (2010) Abstract

Gatza, ML; Lucas, JE; Barry, WT; Kim, JW; Wang, Q; Crawford, MD; Datto, MB; Kelley, M; Mathey-Prevot, B; Potti, A; Nevins, JR. A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences of USA. 2010;107:6994-6999. (2010) Abstract

Pan, H; Ding, E; Hu, M; Lagoo, AS; Datto, MB; Lagoo-Deenadayalan, SA. SMAD4 is required for development of maximal endotoxin tolerance. Journal of Immunology. 2010;184:5502-5509. (2010) Abstract

Horbinski, C; Dacic, S; McLendon, RE; Cieply, K; Datto, M; Brat, DJ; Chu, CT. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathology. 2009;19:439-448. (2009) Abstract

Schilling, SH; Hjelmeland, AB; Radiloff, DR; Liu, IM; Wakeman, TP; Fielhauer, JR; Foster, EH; Lathia, JD; Rich, JN; Wang, XF; Datto, MB. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. Journal of Biological Chemistry. 2009;284:25160-25169. (2009) Abstract

Ma, C; Rong, Y; Radiloff, DR; Datto, MB; Centeno, B; Bao, S; Cheng, AW; Lin, F; Jiang, S; Yeatman, TJ; Wang, XF. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes and Development. 2008;22:308-321. (2008) Abstract

Wooldridge, AA; Fortner, CN; Lontay, B; Akimoto, T; Neppl, RL; Facemire, C; Datto, MB; Kwon, A; McCook, E; Li, P; Wang, S; Thresher, RJ; Miller, SE; Perriard, JC; Gavin, TP; Hickner, RC; Coffman, TM; Somlyo, AV; Yan, Z; Haystead, TA. Deletion of the protein kinase A/protein kinase G target SMTNL1 promotes an exercise-adapted phenotype in vascular smooth muscle. Journal of Biological Chemistry. 2008;283:11850-11859. (2008) Abstract

Kwiek, NC; Thacker, DF; Datto, MB; Megosh, HB; Haystead, TA. PITK, a PP1 targeting subunit that modulates the phosphorylation of the transcriptional regulator hnRNP K. Cellular Signalling. 2006;18:1769-1778. (2006) Abstract

Schilling, SH; Datto, MB; Wang, XF. A phosphatase controls the fate of receptor-regulated Smads. Cell. 2006;125:838-840. (2006) Abstract

Datto, M; Wang, XF. Ubiquitin-mediated degradation a mechanism for fine-tuning TGF-beta signaling. Cell. 2005;121:2-4. (2005) Abstract

Robboy, SJ; Datto, MB. Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries?. Human Pathology. 2005;36:597-599. (2005) Abstract

Moore-Maxwell, CA; Datto, MB; Hulette, CM. Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Modern Pathology. 2004;17:241-247. (2004) Abstract

Zhao, J; Shi, W; Wang, YL; Chen, H; Bringas, P; Datto, MB; Frederick, JP; Wang, XF; Warburton, D. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2002;282:L585-L593. (2002) Abstract

Borton, AJ; Frederick, JP; Datto, MB; Wang, XF; Weinstein, RS. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. Journal of Bone and Mineral Research. 2001;16:1754-1764. (2001) Abstract

Decesse, JT; Medjkane, S; Datto, MB; Crémisi, CE. RB regulates transcription of the p21/WAF1/CIP1 gene. Oncogene. 2001;20:962-971. (2001) Abstract

Datto, M; Wang, XF. The Smads: transcriptional regulation and mouse models. Cytokine and Growth Factor Reviews. 2000;11:37-48. (2000) Abstract

Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB. Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene. 1999;18:2872-2882. (1999) Abstract

Datto, MB; Frederick, JP; Pan, L; Borton, AJ; Zhuang, Y; Wang, XF. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Molecular and Cellular Biology. 1999;19:2495-2504. (1999) Abstract

Haapajärvi, T; Kivinen, L; Heiskanen, A; des Bordes, C; Datto, MB; Wang, XF; Laiho, M. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Experimental Cell Research. 1999;248:272-279. (1999) Abstract

Kivinen, L; Tsubari, M; Haapajärvi, T; Datto, MB; Wang, XF; Laiho, M. Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene. 1999;18:6252-6261. (1999) Abstract

Liberati, NT; Datto, MB; Frederick, JP; Shen, X; Wong, C; Rougier-Chapman, EM; Wang, XF. Smads bind directly to the Jun family of AP-1 transcription factors. Proceedings of the National Academy of Sciences of USA. 1999;96:4844-4849. (1999) Abstract

Rich, JN; Zhang, M; Datto, MB; Bigner, DD; Wang, XF. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. Journal of Biological Chemistry. 1999;274:35053-35058. (1999) Abstract

Wong, C; Rougier-Chapman, EM; Frederick, JP; Datto, MB; Liberati, NT; Li, JM; Wang, XF. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Molecular and Cellular Biology. 1999;19:1821-1830. (1999) Abstract

Hu, PP; Datto, MB; Wang, XF. Molecular mechanisms of transforming growth factor-beta signaling. Endocrine Reviews. 1998;19:349-363. (1998) Abstract

Li, JM; Datto, MB; Shen, X; Hu, PP; Yu, Y; Wang, XF. Sp1, but not Sp3, functions to mediate promoter activation by TGF-beta through canonical Sp1 binding sites. Nucleic Acids Research. 1998;26:2449-2456. (1998) Abstract

Shen, X; Hu, PP; Liberati, NT; Datto, MB; Frederick, JP; Wang, XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Molecular Biology of the Cell. 1998;9:3309-3319. (1998) Abstract

Datto, MB; Hu, PP; Kowalik, TF; Yingling, J; Wang, XF. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Molecular and Cellular Biology. 1997;17:2030-2037. (1997) Abstract

Yingling, JM; Datto, MB; Wong, C; Frederick, JP; Liberati, NT; Wang, XF. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Molecular and Cellular Biology. 1997;17:7019-7028. (1997) Abstract

Datto, MB; Li, Y; Panus, JF; Howe, DJ; Xiong, Y; Wang, XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proceedings of the National Academy of Sciences of USA. 1995;92:5545-5549. (1995) Abstract

Datto, MB; Yu, Y; Wang, XF. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. Journal of Biological Chemistry. 1995;270:28623-28628. (1995) Abstract

Schwarz, JK; Bassing, CH; Kovesdi, I; Datto, MB; Blazing, M; George, S; Wang, XF; Nevins, JR. Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. Proceedings of the National Academy of Sciences of USA. 1995;92:483-487. (1995) Abstract